Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients

Retrieved on: 2022-11-01 11:10:29

Tags for this article:

Click the tags to see associated articles and topics

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients. View article details on hiswai:

Excerpt

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to ...

Article found on: www.elpasoinc.com